Lupin’s wholly-owned subsidiary, Hormosan Pharma GmbH (Hormosan), has launched Luforbec 100/6 in Germany. Luforbec is a fixed-dose combination of beclometasone dipropionate and formoterol fumarate dihydrate, indicated for the long-term, once-daily maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Luforbec is a generic version of Foster 100/6, which is marketed by AstraZeneca. The launch of Luforbec in Germany is the first in a series of planned launches in Europe.
COPD is a chronic lung disease that causes breathing difficulties. It is the third leading cause of death worldwide. Asthma is a chronic inflammatory disease of the airways that causes recurring episodes of wheezing, shortness of breath, chest tightness, and coughing.
Luforbec is a long-acting bronchodilator and corticosteroid combination that works by relaxing the muscles in the airways and reducing inflammation. It is a once-daily treatment that is easy to use and can help to improve lung function and control symptoms.
The launch of Luforbec in Germany is a significant milestone for Hormosan. The company is committed to providing patients with access to affordable, high-quality medicines.
Here are some additional details about the news:
- Luforbec is available in a 100/6 micrograms/dose pressurized metered-dose inhaler (pMDI).
- The recommended dose of Luforbec is one inhalation twice daily.
- Luforbec is contraindicated in patients with a hypersensitivity to beclometasone dipropionate, formoterol fumarate dihydrate, or any of the excipients.
- The most common side effects of Luforbec are cough, headache, and nasopharyngitis.
The launch of Luforbec in Germany is a positive development for patients with asthma and COPD. The drug offers a once-daily treatment option that can help to improve lung function and control symptoms.